[The effect of benzbromaron in gout patients with limited kidney function].
The effect of the uricosuric drug benzdromarone was investigated in 15 patients with hyperuricemia and renal failure. Benzbromarone micron was given in a dose of 80 mg/day for 6 days. The mean serum uric acid level fell from 8.9 to 4.24 mg/100 ml. After therapy uric acid concentrations in serum returned to 5.2 mg/100 ml. Renal urate elimination was increased from 487 mg/day to 831.3 mg/day; after medication urate elimination decreased to the initial values. Uric acid clearance was increased by benzbromarone from 3.97 to 11.1 ml/min, and even after therapy a uric acid clearance of 6.4 ml/min could be measured. A decrease of uric acid reabsorption from 4.73 to 2.3 mg/min was observed, after medication the reabsorption rate increased to 3.42 mg/min.
D000328:Adult; D000368:Aged; D001553:Benzbromarone / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004341:Drug Evaluation; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D007674:Kidney Diseases / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood
D001572:Benzofurans; D014527:Uric Acid; D001553:Benzbromarone; D003404:Creatinine
Zur Wirkung von Benzbromaron bei Gicht-Patienten mit eingeschränkter Nierenfunktion.